AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Nov 18, 2020

AbbVie Announces Expiration and Final Results of Registered Exchange Offers

NORTH CHICAGO, Ill., Nov. 18, 2020 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the expiration and final results of its offers to exchange (the "Registered Exchange Offers") any and all of its outstanding (i) $30,000,000,000 aggregate principal amount of senior unsecured notes previously issued on November 21, 2019 (the "2019 USD Notes"), (ii) $13,251,781,000 aggregate principal amount of senior unsecured notes previously issued on May 14, 2020 (the "2020 USD Notes" and, together with the 2019 USD Notes, the "USD Notes") and (iii) €2,517,066,000 aggregate principal amount of senior unsecured notes previously issued on May 14, 2020 (the "Euro Notes" and, together with the USD Notes, the "Original Notes"), each issued pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), for an equal principal amount of new notes in a transaction registered under the Securities Act (the "Registered Notes").

Nov 16, 2020

Allergan Aesthetics Celebrates Second Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day

IRVINE, Calif., Nov. 16, 2020 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating its second annual BOTOX® Cosmetic Day on Wednesday, November 18, 2020. The event is dedicated to celebrating the iconic treatment that helped create the aesthetics industry and recognizing the loyal community of patients and healthcare providers who have helped make this brand what it is today. In addition, this is a day for both new and loyal BOTOX® Cosmetic users to put themselves first with an exclusive one-day-only offer available while supplies last exclusively through AllēSM, the new loyalty platform from Allergan Aesthetics.

Nov 16, 2020

New Alliance to Address Multiple Pain Points for Women Living with Endometriosis

Washington, D.C., Nov. 16, 2020 (PR NEWSWIRE) – Today, seven women’s health-focused organizations – the American College of Obstetricians and Gynecologists (ACOG), the Endometriosis Association, AbbVie, HealthyWomen, the International Pelvic Pain Society (IPPS), GE Healthcare and Black Women’s Health Imperative (BWHI) – announced the formation of the Alliance for Endometriosis to improve the lives of the one in 10 women of reproductive age living with this disease in the United States.
Nov 12, 2020

AbbVie to Present at the Wolfe Research Healthcare Conference

NORTH CHICAGO, Ill., Nov. 12, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on Thursday, November 19, 2020. Michael Severino, M.D., vice chairman and president, and Robert A. Michael, executive vice president and chief financial officer, will present at 11:35 a.m. Central time.

Nov 06, 2020

Allergan, an AbbVie company, to Share New Data at American Academy of Ophthalmology (AAO) 2020 Virtual

NORTH CHICAGO, Ill., Nov. 6, 2020 – Allergan, an AbbVie Company, today announced that it will present new data advancing scientific understanding of an intraocular pressure (IOP) lowering treatment in glaucoma and evaluating an investigational treatment for presbyopia at American Academy of Ophthalmology (AAO) 2020 Virtual (November 13-15).
Nov 05, 2020

AbbVie to Highlight Blood Cancer Leadership and Advancing Oncology Pipeline at the ASH 62ND Annual Meeting

NORTH CHICAGO, Ill., Nov. 5, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that it will present blood cancer data from nearly 40 abstracts, including 10 oral presentations, across 11 cancer types during the upcoming virtual American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8.

Oct 30, 2020

AbbVie Reports Third-Quarter 2020 Financial Results

NORTH CHICAGO, Ill., Oct. 30, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced financial results for the third quarter ended September 30, 2020.

Oct 29, 2020

AbbVie to Present New Analyses from Pivotal Phase 3 Studies for RINVOQ™ (upadacitinib) in Atopic Dermatitis

NORTH CHICAGO, Ill., Oct. 29, 2020 /PRNewswire/ -- Late-breaking data analyses to be presented by AbbVie (NYSE: ABBV) at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress show that significantly more atopic dermatitis patients treated with upadacitinib (15 mg or 30 mg; once daily) monotherapy achieved improvement in additional measures of skin clearance and reduction in itch compared to placebo.1 These data are from the Phase 3 Measure Up 1 and Measure Up 2 studies, which support the recent applications to the U.S. Food and Drug Administration and European Medicines Agency, seeking approval for RINVOQ in adult and adolescent patients with moderate to severe atopic dermatitis.

Oct 28, 2020

AbbVie Highlights Innovative Research for People with Rheumatic Diseases with New Data at ACR Convergence 2020

NORTH CHICAGO, Ill., Oct. 28, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of new data on RINVOQ™ (upadacitinib) and HUMIRA® (adalimumab) across multiple rheumatic diseases at the American College of Rheumatology's annual meeting (ACR Convergence 2020), to be held virtually November 5-9. A total of 38 abstracts, including seven oral presentations, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

Oct 28, 2020

Allergan, an AbbVie Company, Announces Positive Phase 3 Topline Results for Investigational AGN-190584 for the Treatment of Presbyopia

NORTH CHICAGO, Ill., Oct. 28, 2020 /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced the Phase 3 GEMINI 1 and 2 clinical trials evaluating the efficacy, safety and tolerability of investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of symptoms associated with presbyopia, met their primary efficacy endpoint. Additional details of these studies will be presented at future medical meetings and will serve as the basis for the New Drug Application submission to U.S. Food and Drug Administration (FDA) in the first half of 2021.